Intravesical Upgrade: Preventing Recurrence in Non-Muscle Invasive Bladder Cancer

Challenge Number : #03

Nominate your targeted or muco-adhesive partner to combine with gemcitabine or mitomycin C, targeting the high recurrence rates (>40-50% at 5 years) in NMIBC and delivering a breakthrough in bladder-sparing therapy.

Challenge Entry Fee: $10,000.00

Reward Amount: $400,000

Description

Intravesical gemcitabine or mitomycin C remains a cornerstone for non-muscle invasive bladder cancer (NMIBC) post-TURBT, but recurrence rates stay high—often 40-50% at 5 years and up to 60-80% in some series—due to incomplete tumor eradication and limited penetration/control of regrowth.

FUSIONx challenges biotechs to nominate innovative partners (e.g., targeted agents, muco-adhesive formulations) for combination testing on abundant, viable TURBT tissue chips in our ex-vivo platform. By assessing full microenvironment dynamics, we aim to identify synergies that prevent regrowth, reduce recurrence, and improve durable responses—potentially shifting standards in this high-volume indication. In a $6B+ bladder cancer market with rising BCG-unresponsive needs, success could accelerate bladder-sparing options, attract innovator partnerships (e.g., to complement emerging ADCs/IO), and drive significant clinical and commercial upside.

Standalone Compound Assessment
The Participation Framework

STRATEGIC TERMS & INCENTIVES

Empowering Biotech Innovation through Flexible Collaboration

The Investment Model:

  • Entry Protocol: $10,000 total entry fee.
  • Performance Prize: $400,000 cash award for compounds achieving ≥50% synergy across 5 human tissues.
  • The “Near-Miss” Accelerator: Compounds achieving 40–50% synergy receive a complimentary validation across 5 additional tissues.
  • Enhanced Assessment: Optional Standalone Assessment available for an additional $10,000.
  • Pathways to Commercialization (The Dual-Choice Model): To ensure IP security and alignment, participants select one of two specialized commercial paths upon a successful match:
  • Path A (The Prize Path): Receive the $400,000 cash prize plus a 45% equity stake in a FUSIONx-led spin-off entity for the combo.
  • Path B (The Ownership Path): Retain 100% IP and ownership of the combination and spin-off. FUSIONx waives the cash prize in exchange for a minor royalty/milestone interest (10%).

 

The Logistics Flow

  • Submission: Fill out dosing data and pay Participation Fee ($10,000) via Stripe.
  • Delivery: Receive compound shipping instructions for the Israel lab.
  • Analysis: Lab performs functional synergy testing against the anchor asset.
  • Finalization: Receive the full Synergy Report.

 

The Win/Win Outcomes

  • The Prize: The best match among the first 40 submittors wins the reward (split if multiple winners).
  • The Value: Even if not winning, participants get a report on their compound’s synergy performance on 5 tissues.
  • Optional: Participants can get a report on their compound’s standalone performance on 5 tissues for an additional $10,000.